GlassScriptPhysician profile
Mariam Naveed
NPI 1477797371
$21,899.46
in general payments reported to CMS, 2019-2025
22 companies · $8,489 in 2025
The $8,489 reported for 2025 was more than what 92% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $245 · 2022: $489 · 2023: $769 · 2024: $12K · 2025: $8,489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,822 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,903 · Food and Beverage: $2,565 · Travel and Lodging: $876.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,822.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,902.50 |
| Food and Beverage | $2,565.14 |
| Travel and Lodging | $876.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $11,111.32 | 2024-2025 | |
| Olympus America INC. | $7,902.50 | 2024-2025 | Evis Exera III Colonovideoscope, Gastrointestinal Videoscope, Evis Exera III Video System Center |
| Abbvie INC. | $915.56 | 2021-2025 | |
| Janssen Scientific Affairs, LLC | $251.69 | 2023-2025 | Tremfya, Stelara |
| Cook Medical LLC | $228.81 | 2023-2025 | Echotip Insight, Echotip, Hemospray |
| Boston Scientific Corporation | $220.28 | 2022-2025 | Axonics |
| Janssen Biotech, INC. | $184.25 | 2022-2024 | Tremfya, Stelara |
| Medtronic, INC. | $171.43 | 2023-2024 | Prodigi, Barrx |
| Ferring Pharmaceuticals INC. | $144.91 | 2023 | Rebyota |
| Regeneron Pharmaceuticals, INC. | $139.47 | 2022 | |
| Conmed Corporation | $139.01 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $124.86 | 2021 | |
| Edwards Lifesciences Corporation | $92.21 | 2024 | Hemosphere |
| Becton, Dickinson and Company | $71.11 | 2025 | Hemosphere |
| Mentor Worldwide LLC | $69.42 | 2024 | Mentor Memorygel Resterilizable Gel Sizer |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $26.08 | 2024 | Zepbound, Omvoh |
| Madrigal Pharmaceuticals | $24.82 | 2025 | Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $21.23 | 2023 | |
| Phathom Pharmaceuticals, INC. | $17.99 | 2025 | Voquezna |
| Evoke Pharma, INC. | $15.91 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.33 | 2023 | Entyvio |
| Mallinckrodt Hospital Products INC. | $13.27 | 2023 | Terlivaz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mariam Naveed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.